Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 3 Interventional

A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

ClinicalTrials.gov ID: NCT07702578

Public ClinicalTrials.gov record NCT07702578. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 5:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/3 Study Evaluating the Efficacy and Safety of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a multicenter, genetically-randomized, controlled, Phase 3 study evaluating the efficacy and safety of T-cell receptor-engineered donor T cells targeting HA-2 (TSC-101) administered following reduced-intensity conditioning (RIC) hematopoietic cell transplantation (HCT) in participants with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The study will compare TSC-101 plus standard of care (SOC) versus SOC alone in participants undergoing allogeneic peripheral blood stem cell transplantation from haploidentical or mismatched unrelated donors.

Study identification

NCT ID
NCT07702578
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
TScan Therapeutics, Inc.
Industry
Enrollment
310 participants

Conditions and interventions

Conditions

Interventions

Drug · Other

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 17, 2026
Primary completion
May 31, 2029
Completion
May 31, 2029
Last update posted
Jul 21, 2026

2026 – 2029

United States locations

U.S. sites
26
U.S. states
18
U.S. cities
24
Facility City State ZIP Site status
Banner Health - MD Anderson Cancer Center Gilbert Arizona 85234 Not yet recruiting
Honor Health Cancer Transplant Institute Scottsdale Arizona 85258 Not yet recruiting
City of Hope Duarte California 91010 Recruiting
Stanford - School of Medicine Stanford California 94305 Not yet recruiting
University of Colorado - Anschutz Cancer Center Aurora Colorado 80045 Recruiting
SCRI - Colorado Blood Cancer Institute Denver Colorado 80218 Recruiting
Yale New Haven Connecticut 06510 Recruiting
Memorial Cancer Institute Hollywood Florida 33021 Recruiting
Moffitt Cancer Institute Tampa Florida 33612 Recruiting
Northside Hospital Atlanta Georgia 30342 Recruiting
University of Chicago Chicago Illinois 60607 Not yet recruiting
The University of Kansas Cancer Center Kansas City Kansas 66160 Not yet recruiting
Johns Hopkins University Baltimore Maryland 21287 Recruiting
Massachusetts General Hospital Boston Massachusetts 02114 Recruiting
Dana-Farber Cancer Institute - Hematology/Oncology Boston Massachusetts 02215 Recruiting
Karmanos Cancer Institute Detroit Michigan 48201 Recruiting
Hackensack University Medical Center Hackensack New Jersey 07601 Recruiting
Mount Sinai Hospital New York New York 10029 Recruiting
Columbia University - Irving Medical Center New York New York 10032 Recruiting
The University of North Carolina at Chapel Hill Chapel Hill North Carolina 27599 Recruiting
Hospital of the University of Pennsylvania Philadelphia Pennsylvania 19104 Recruiting
Sarah Cannon Research Institute - TriStar Bone Marrow Transplant (BMT) Nashville Tennessee 37203 Recruiting
St. David's South Austin Medical Center Austin Texas 76704 Recruiting
Baylor University Medical Center Dallas Texas 75246 Recruiting
The University of Texas - MD Anderson Cancer Center Houston Texas 76704 Recruiting
Froedtert & Medical College of Wisconsin Milwaukee Wisconsin 53226 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07702578, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 21, 2026 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07702578 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →